HOT TOPICS IN
INFECTION AND IMMUNITY
IN CHILDREN III

ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY

Editorial Board:

NATHAN BACK, *State University of New York at Buffalo*

IRUN R. COHEN, *The Weizmann Institute of Science*

DAVID KRITCHEVSKY, *Wistar Institute*

ABEL LAJTHA, *N.S. Kline Institute for Psychiatric Research*

RODOLFO PAOLETTI, *University of Milan*

Recent Volumes in this Series

Volume 574

LIVER AND PANCREATIC DISEASES MANAGEMENT

Edited by Nagy A. Habib and Ruben Canelo

Volume 575

DIPEPTIDYL AMINOPEPTIDASES: BASIC SCIENCE AND
CLINICAL APPLICATIONS

Edited by Uwe Lendeckel, Ute Bank, and Dirk Reinhold

Volume 576

N-ACETYLASPARTATE: A UNIQUE NEURONAL MOLECULE IN THE
CENTRAL NERVOUS SYSTEM

Edited by John R. Moffett, Suzannah B. Tieman, Daniel R. Weinberger,
Joseph T. Coyle and Aryan M.A. Namboodiri

Volume 577

EARLY LIFE ORIGINS OF HEALTH AND DISEASE

Edited by E. Marelyn Wintour and Julie A. Owens

Volume 578

OXYGEN TRANSPORT TO TISSUE XXVII

Edited by Giuseppe Cicco, Duane Bruley, Marco Ferrari, and
David K. Harrison

Volume 579

IMMUNE MECHANISMS IN INFLAMMATORY BOWEL DISEASE

Edited by Richard S. Blumberg

Volume 580

THE ARTERIAL CHEMORECEPTORS

Edited by Yoshiaki Hayashida, Constancio Gonzalez, and Hisatake Condo

Volume 581

THE NIDOVIRUSES: THE CONTROL OF SARS AND OTHER
NIDOVIRUS DISEASES

Edited by Stanley Perlman and Kathryn Holmes

Volume 582

HOT TOPICS IN INFECTION AND IMMUNITY IN CHILDREN III

Edited by Andrew J. Pollard and Adam Finn

A Continuation Order Plan is available for this series. A continuation order will bring delivery of each new volume immediately upon publication. Volumes are billed only upon actual shipment. For further information please contact the publisher.

HOT TOPICS IN INFECTION AND IMMUNITY IN CHILDREN III

Edited by

Andrew J. Pollard

*University of Oxford
Oxford, United Kingdom*

Adam Finn

*University of Bristol
Bristol, United Kingdom*

Springer

Andrew J. Pollard
University of Oxford
Level 4, John Radclif Hospital
Oxford, UK OX3 9DU

Adam Finn
University of Bristol
Tyndall Avenue
Bristol, UK B58 1TH

Library of Congress Control Number: 2005939184

ISBN-10: 0-387-31783-X

ISBN-13: 978-0387-31783-0

Printed on acid-free paper.

© 2006 Springer Science+Business Media, LLC

All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights.

Printed in the United States of America. (BS/MVY)

9 8 7 6 5 4 3 2 1

springer.com

Preface

This book is based on the course “Infection and Immunity in Children 2005” which was held at St Catherine’s College Oxford, UK in June 2005. This is the third book in this series covering topics in infection and immunity during childhood and based on the Oxford courses. These courses, and their companion books, are aimed at encouraging excellence in clinical practice and raising the profile of paediatric infectious disease with a particular eye on the needs of trainees in the specialty. At the time of writing a fourth course is already at an advanced stage of planning for June 2006 with a completely new programme once again.

You will find in this book a wealth of state of the art information about various aspects of paediatric infectious diseases written by leading authorities in the field. We hope this volume will bring new insights into the management of children with infectious diseases and improve the health of children.

Andrew J Pollard and Adam Finn
January 2006

Acknowledgments

We are indebted to all of the contributors to this text who have generously provided their carefully written manuscripts in good time for editing and publication. We are also grateful to the staff of St Catherine's College, Oxford, UK who hosted *Infection and Immunity in Children 2005* on which the text is based.

We are particularly grateful to Sue Sheaf for the administration of the Course and who assisted with the preparation of the edited manuscripts and to our colleagues and families who supported our own activities in this venture. Our gratitude also for the support provided by the European Society for Paediatric Infectious Disease (ESPID), the British Paediatric Allergy Infection and Immunity Group (BPAIIG), and the Royal College of Paediatrics and Child Health (RCPCH). Lastly, we are pleased to acknowledge the generous and unrestricted financial support of Sanofi Pasteur MSD, Chiron Vaccines, GlaxoSmithKline Vaccines, and Wyeth Vaccines who made the meeting possible.

Contents

Contributing Authors	xix
-----------------------------------	-----

1. Warfare and the State of the World’s Children

Frank Shann

1. Introduction	1
2. Direct Effects of War	2
3. Indirect Effects of War	3
4. Sustainable Development	3
5. Military Expenditure	4
6. What can be Done?	5
7. Some Good News – Costa Rica	6
8. Conclusion	6
References	7

2. How do We Treat Children with Severe Malaria?

Kathryn Maitland

1. Introduction	9
2. Epidemiological Considerations	9
3. Pre-hospital Management	10
4. Parasitological Diagnosis	11
5. Assessment and Triage of Children with Severe Malaria	12
5.1. Generic Approached to Management	12
5.2. Identification and Management of Shock	13
5.2.1. Volume Resuscitation	14
5.3. The Child with Impaired Consciousness (GCS ≤ 8)	15
6. Monitoring	16
6.1. Blood Tests	16
6.2. Other Laboratory Investigations	16
7. General Management	16
7.1. Antimalarial Medication	16
7.2. Role of Exchange Transfusion	17
8. Outcome	18
References	19

3. The Neglected Tropical Diseases: The Ancient Afflictions of Stigma and Poverty and the Prospects for their Control and Elimination

Peter Hotez, Eric Ottesen, Alan Fenwick, and David Molyneux

1. Introduction	23
2. The NTDs as the Ancient Afflictions of Stigma and Poverty	24
3. The Role of the Pharmaceutical Industry	26
4. New Promise through Public Private Partnerships	27
5. Vertical Controls Efferts	29
6. Integrated Control	30
7. New Generation Control Tools	30
Acknowledgements	31
References	31

4. Viral Haemorrhagic Fevers Caused by Lassa, Ebola and Marburg Viruses

Nigel Curtis

1. Introduction	35
2. Epidemiology	37
2.1. Lassa Fever	37
2.2. Ebola and Marburg Fever	37
3. Transmission	38
3.1. Lassa Fever	38
3.2. Ebola and Marburg Fever	38
4. Virology	39
4.1. Lassa Virus	39
4.2. Ebola and Marburg Viruses	39
5. Clinical Features	39
5.1. Lassa Fever	39
5.2. Lassa Fever in Pregnancy and Children	40
5.3. Ebola and Marburg Fever	40
6. Pathogenesis	41
7. Differential Diagnosis	41
8. Treatment	41
9. Prevention and Control Measures	42
9.1. Vaccine	42
9.2. Community Awareness, Education and Other Control Measures	42
10. Recognition and Management of Supected Cases of Viral Haemorrhagic Fever	42
11. Infection Control	43
Acknowledgements	43
References	43

5. Rotavirus and Rotavirus Vaccines

*Roger I. Glass, Joseph Bresee, Baoming Jiang,
Umesh Parashar, Eileen Yee, and Jon Gentsch*

1. Introduction to Diarrhea in Children	45
2. The Role of Rotavirus	46
2.1. The Epidemiology of Rotavirus and the Natural History of the Disease	46
2.2. The Pathogenesis of Rotavirus Diarrhea	47
2.3. Diagnostics and Virology	47
2.4. The Mechanism of Immunity	48
2.5. The Burden of Rotavirus Disease	48
3. Vaccines as an Approach to Control	49
3.1. The Earliest Vaccine	49
3.2. Rhesus Tetravalent Vaccine – Rotashield	49
3.3. The Current Generation of Vaccines	50
3.4. Future Vaccines in the Pipeline	51
4. Looking into the Future	52
4.1. The Goal for Rotavirus Vaccines	52
4.2. Challenges for the Future	52
5. Summary	53
References	54

6. Transient Deficiencies of T-Cell-Mediated Immunity in
the Neonate

David A. Randolph and David B. Lewis

1. Introduction	55
2. Overview of T-Cell-Mediated Immunity	55
2.1. CD4 ⁺ T Cells	56
2.2. T Helper 1 Cells	56
2.3. CD8 ⁺ T Cells	58
3. Clinical Evidence for Deficiencies of T-Cell-Mediated Immunity in the Neonate	59
4. Cellular and Molecular Basis for Impaired T-Cell-Mediated Immunity ...	62
4.1. Impaired Dendritic Cell Function	62
4.2. Impaired T Helper 1 Function	63
4.3. Reduced CD154 Expression	65
5. Conclusions	67
References	67

7. Controversies in Neonatal Sepsis: Immunomodulation in
the Treatment and Prevention of Neonatal Sepsis

Samantha J. Moss and Andrew R. Gennery

1. Introduction	71
2. Background to Neonatal Infection	71

2.1. Difficulties in Interpreting Blood Culture Results 71

2.2. Epidemiology 72

2.3. Factors Pre Disposing to Neonatal Infection 72

 2.3.1. Extrinsic Factors 72

 2.3.2. Intrinsic Factors 73

 2.3.2a. The Innate Immune Response 73

 2.3.2b. Immunoglobulin Production and B Cell Function 73

3. Use of Granulocyte Infusions in the Treatment of Neonatal Sepsis 74

4. Use of Growth Factors in Neonatal Sepsis 75

 4.1. Growth Factors to Treat Neonatal Sepsis 76

 4.2. Prophylactic Growth Factors for the Prevention of Neonatal Sepsis .. 77

5. Use of Pooled Human Immunoglobulin in Neonatal Sepsis 78

 5.1. Role of Intravenous Immunoglobulin Infusions in the Treatment of Suspected or Proven Neonatal Sepsis 78

 5.2. Role of Prophylactic Intravenous Immunoglobulin Infusions in the Prevention of Neonatal Sepsis 79

6. Conclusion 80

Acknowledgements 80

References 80

8. *Chlamydia trachomatis* Genital Infection in Adolescents and Young Adults

Toni Darville

1. Introduction 85

2. The Pathogen 86

 2.1. Chlamydial Developmental Cycle 86

 2.2. Classification 87

3. Pathogenesis 87

 3.1. Immunopathogenesis 87

 3.2. Immunoprotection 88

4. Epidemiology 89

5. Clinical Manifestations 91

 5.1. Infections in Males 91

 5.2. Infections in Females 92

6. Diagnosis 93

 6.1. Diagnostic Specimens 93

 6.2. Cell Culture 93

 6.3. Non-Culture Tests 94

 6.4. Serology 94

7. Treatment 94

8. Complications and Sequelae 95

9. Prevention 95

10. Future Directions 96

Acknowledgements 97

References 97

9. The Role of Inflammation and Infection in the Development of Chronic Lung Disease of Prematurity	
<i>Philip L. Davies, Nicola C. Maxwell, and Sailesh Kotecha</i>	
1. Introduction	101
2. Lung Development	102
3. Lung Inflammation in CLD	102
4. Antenatal Inflammation	103
5. Antenatal Infection and Preterm Delivery	104
6. Antenatal and Postnatal Infection and CLD	105
7. <i>Ureaplasma Urealyticum</i>	106
8. Summary	107
References	108
10. <i>Streptococcus pneumoniae</i>: Infection, Inflammation and Disease	
<i>Tim J. Mitchell</i>	
1. Introduction	111
2. Virulence Factors Produced by the Pneumococcus	112
2.1. The Pneumococcal Cell Surface	112
2.1.1. Choline-binding Proteins	112
2.1.2. LPXTG-anchored Proteins	113
2.1.3. Lipoproteins	113
2.1.4. Other Surface Proteins	114
2.2. Pneumolysin	114
2.2.1. Biological Properties of Pneumolysin	114
2.2.2. Variation in Pneumolysin Sequence and Activity in Serotype 1 Pneumococci	115
2.2.3. Pneumolysin as a Vaccine Candidate	117
2.3. Other Virulence Factors	118
3. Conclusions	118
References	118
11. Impact of Antimicrobial Resistance on Therapy of Bacterial Pneumonia in Children	
<i>B. Keith English and Steven C. Buckingham</i>	
1. Introduction	125
2. Epidemiology of Bacterial Pneumonia in Children	127
3. Impact of Discordant Empiric Therapy on Outcome in Pediatric Pneumonia	129
3.1. Beta-lactam Resistance in <i>Streptococcus pneumoniae</i>	129
3.2. Emergence of CA-MRSA as a Cause of Pneumonia in Otherwise Healthy Children	130
4. Summary, Conclusions, and Recommendations	131
References	132

12. Diagnosis and Prevention of Pneumococcal Disease

Hanna Nohynek

1. Introduction 137

2. From Carriage to Clinical Disease 138

3. Methods to Detect Involvement of *Streptococcus pneumoniae*
in Disease 138

3.1. Direct, Specific Means to Detect Pneumococci 138

3.2. Indirect, Specific Means to Detect Pneumococcal Involvement 139

3.3. Nonspecific Means to Detect Pneumococcal Involvement 140

3.3.1. Radiology 140

3.3.2. Acute Phase Reactants 141

4. Measuring the Disease Burden Caused by Pneumococcus 141

5. Immunity to and Prevention of Pneumococcal Diseases 142

5.1. The Different Pneumococcal Structures and Vaccines Directed
Against Them 142

5.2. The Overall Protective Effect of Pneumococcal Vaccines 143

5.3. The Effect of Conjugated Pneumococcal Vaccines on Different
Forms of Pneumococcal Disease 143

5.3.1. Invasive Disease 143

5.3.2. Pneumonia 143

5.3.3. Acute Otitis Media 145

5.3.4. Nasopharyngeal Carriage 145

5.3.5. Herd Immunity Effect 145

5.4. Introduction of Pneumococcal Vaccines into National Vaccination
Programs 146

6. Future Directions 146

References 147

13. New Antibiotics for Gram-Positive Infections

John S. Bradley

1. Introduction 151

2. The Pathogens 151

3. Older Antibiotics 153

4. Newer Antibiotics 153

4.1. Linezolid 153

4.2. Fluoroquinolones 155

4.3. Daptomycin 155

4.4. New Glycopeptides 156

4.5. Ceftobiprole 159

4.6. Telithromycin 160

4.7. Tigecycline 161

5. In the Pipeline 162

References 162

14. Clinical Manifestations of Nontuberculous Mycobacteria

Robert S. Heyderman and Julia Clark

1. Introduction 167

2. Epidemiology 167

3. Laboratory Diagnosis and Antimicrobial Resistance Testing 168

4. NTM in Otherwise Healthy Children 169

 4.1. NTM Lymphadenitis 169

 4.2. Other Soft Tissue Infections 171

5. NTM in Immunocompromised Children 171

 5.1. Patients with Cystic Fibrosis 171

 5.2. Patients with Leukemia or Cancer 173

 5.3. Patients with Familial Disorders 173

6. Principles of Drug Therapy 174

Acknowledgements 175

References 175

15. *Kingella kingae*: an Emerging Pediatric Pathogen

Pablo Yagupsky

1. Introduction 179

2. Detection of *K. kingae* 180

 2.1. Detection by Culture 180

 2.2. Detection by Nucleic Acid Amplification Techniques 181

3. Clinical Presentation of *K. kingae* Infections 181

4. Epidemiology of *K. kingae* Infections 183

 4.1. Age and Gender Distribution of Patients with Invasive *K. kingae* Disease 183

 4.2. Carriage of *K. kingae* 184

 4.3. Seasonal Distribution of Invasive *K. kingae* Infection 185

 4.4. Outbreaks of Invasive *K. kingae* Infections in Daycare Centers 185

5. Immune Response to Respiratory Carriage and Invasive Infection 186

6. Pathogenesis of *K. kingae* Infections 187

7. Management of *K. kingae* Infections 188

 7.1. Antibiotic Susceptibility of *K. kingae* 188

 7.2. Antibiotic Treatment of *K. kingae* Infections 188

8. Conclusions 189

References 189

16. How to Treat Acute Musculoskeletal Infections in Children

Nico G. Hartwig

1. Summary 191

2. Introduction 191

3. Aetiology and Pathogenesis 192

4. Signs and Symptoms 193

5. Diagnosis	194
6. Treatment	195
7. Complications	199
8. Prognosis	199
9. Prevention	199
References	200
17. Prevention of Transmission of HIV-1 from Mothers to Infants in Africa	
<i>Hoosen Coovadia and Derseree Archary</i>	
1. Introduction	201
2. Success, Failures & Barriers	202
3. Risks of Mother-to-Child-Transmission of HIV-1	203
4. Prevention Trials	205
4.1. Industrialized Countries	205
4.2. Developing Countries	205
4.3. Recent Trials of Combination ARVs in Non-Breastfeeding Populations	211
4.4. Recent Trials of Combination ARVs in Breastfeeding Populations ...	212
5. Development of Resistance To Nevirapine	213
6. Conclusions	214
References	216
18. Practical Aspects of Antiretroviral Treatment in Children	
<i>Sam Walters</i>	
1. Introduction	221
2. Aims of Therapy	221
3. Selection of the Combination	222
3.1. Potency vs Practicality	222
3.2. Resistance Assays	222
3.3. Practicality	222
3.4. Convenience	223
3.5. Choice of Drugs	223
3.6. Principles and Practicality	224
3.7. Short Term Side Effects	224
3.8. Specific Side Effects	225
3.8.1. Rash	225
3.8.2. GI Symptoms	225
3.8.3. Mitochondrial Toxicity	225
4. Maintaining Therapy	226
4.1. Adherence	226
4.2. Follow-up Appointments	226

4.3. Long-Term Side Effects	226
4.3.1. Lipid Disturbance	226
4.4. Changing Drugs	227
5. Treatment Interruption	227
6. Conclusion	227
References	227
 19. Antibiotic Treatment for Acute Otitis Media in Children	
<i>Matthew J. Thompson and Paul Glasziou</i>	
1. Introduction	229
2. Risk Factors for AOM	230
3. Diagnosis of AOM	230
4. Treatment of AOM	231
4.1. Effects on Short-term Outcomes	232
4.2. Effects on Medium-Term Outcomes	232
4.3. Effects on Serious Sequelae of AOM	233
4.4. Adverse Effects of Antibiotics	235
5. Duration and Type of Antibiotics Used in AOM	236
6. Limitations of Current Evidence	236
7. Prevention of AOM	238
8. Conclusions	238
References	239
 20. Antibiotic Prophylaxis for the Prevention of Recurrent Urinary Tract Infections in Children	
<i>Elliot Long, Samantha Colquhoun, and Jonathan R. Carapetis</i>	
1. Introduction	243
2. Why Prevent Urinary Tract Infections in Children?	243
3. Which Children are at Risk of Recurrent UTI?	245
4. Can Recurrent Urinary Tract Infections be Prevented?	245
5. Is There Any Harm Associated with the Long-Term Use of Antibiotic Prophylaxis?	246
6. Do Non-antibiotic Interventions Have a Role in Preventing Recurrent Urinary Tract Infections?	247
7. Recommendations for the Use of Antibiotic Prophylaxis	247
Acknowledgements	248
References	248
 21. Human Metapneumovirus: An Important Cause of Acute Respiratory Illness	
<i>Adilia Warris and Ronald de Groot</i>	
1. Introduction	251
2. Characterization of the Virus	251
3. Molecular Epidemiology	253

4. Clinical Epidemiology	254
5. Pathogenesis	254
6. Diagnosis	257
7. Clinical Characteristics	258
8. Therapy	261
9. Prevention	261
10. Conclusions	262
References	262
Index	265

Contributing Authors

Derseree Archary

Department of Paediatrics and Child
Health
University of KwaZulu-Natal
Nelson R Mandela School of Medicine
2nd Floor Doris Duke Medical Research
Institute
Private Bag 7
Congella
Durban 4013, South Africa

John S. Bradley

Division of Infectious Diseases
Children's Hospital
San Diego
CA 92123
USA

Joseph Bresee

Viral Gastroenteritis Section
CDC
1600 Clifton Road
Atlanta, GA 30333
USA

Jonathan R. Carapetis

Director, Centre for International Child
Health
Consultant in Paediatric Infectious
Diseases
University of Melbourne Department of
Paediatrics
Royal Children's Hospital
Parkville VIC 3052
Australia

Julia Clark

Paediatric Infectious Diseases Unit
Newcastle General Hospital
Newcastle upon Tyne NE4 6BE
UK

Samantha Colquhoun

Research Coordinator
Centre International Child Health
University of Melbourne, Department of
Paediatrics, and
Murdoch Childrens Research Institute
Royal Children's Hospital
Parkville. Vic
Australia

Hoosen Coovadia

Centre for HIV and AIDS Networking
(HIVAN)
University of KwaZulu-Natal
Nelson R Mandela School of Medicine
2nd Floor Doris Duke Medical Research
Institute
Private Bag 7
Congella
Durban 4013, South Africa

Nigel Curtis

Department of Paediatrics
University of Melbourne and
Paediatric Infectious Diseases Unit
Department of General Medicine and
Murdoch Children's Research Institute
Royal Children's Hospital
Parkville VIC 3052
Australia

Toni Darville

Division of Pediatric Infectious Diseases
Department of Pediatrics and
Microbiology/Immunology
University of Arkansas for Medical
Sciences
Little Rock
Arkansas
USA

Philip L. Davies

Department of Child Health
Cardiff University
Cardiff
CF14 4XN
UK

B. Keith English

The University of Tennessee Health
Science Center
Memphis
Tennessee
USA

Alan Fenwick

Director of Schistosomiasis Control
Initiative
Department of Infectious Disease
Epidemiology
Imperial College
London, UK

Andrew R. Gennery

Paediatric Immunology Department
Newcastle General Hospital
Newcastle upon Tyne
NE4 6BE
UK

Jon Gentsch

Viral Gastroenteritis Section
CDC
1600 Clifton Road
Atlanta, GA 30333
USA

Roger Glass

Viral Gastroenteritis Section
CDC
1600 Clifton Road
Atlanta, GA 30333
USA

Paul Glasziou

Department of Primary Health Care
University of Oxford
Old Road Campus
Oxford OX3 7LF UK

Ronald de Groot

Pediatric Infectious Diseases Specialist
Professor and Head of the Pediatric
Department
Radboud University Medical Center
Nijmegen
P.O. Box 9101
6500 HB Nijmegen, the Netherlands

Robert S. Heyderman

Department of Cellular & Molecular
Medicine
School of Medical Sciences
University of Bristol
University Walk
Bristol BS8 1TD, UK

Nico G. Hartwig

Paediatric Infectious Diseases Specialist
Department of Paediatrics
Erasmus MC-Sophia
Rotterdam
The Netherlands

Peter Hotez

Department of Microbiology, Immunology
and Tropical Medicine
The George Washington University and
Sabin Vaccine Institute
Washington DC 20037
USA

Baoming Jiang

Viral Gastroenteritis Section
CDC
1600 Clifton Road
Atlanta, GA 30333
USA

Eileen Lau

Viral Gastroenteritis Section
CDC
1600 Clifton Road
Atlanta, GA 30333
USA

David B. Lewis

Department of Paediatrics and the Program
in Immunology
Stanford University
CCSR Building
Room 2115
Stanford University School of
Medicine
269 Campus Drive
Stanford, CA 94305-5164
USA

Elliot Long

Paediatric Registrar
Royal Children's Hospital
Parkville Victoria 3052 Australia

Sailesh Kotecha

Department of Child Health
Cardiff University
Cardiff CF14 4XN

Kathryn Maitland

The Centre for Geographic Medicine
Research
Coast, Kemri, Kenya
PO Box 230
Kilifi, Kenya
and
Department of Academic Paediatrics
Imperial College, London, UK

Nicola C. Maxwell

Department of Child Health
Cardiff University
Cardiff
CF14 4XN, UK

Tim J. Mitchell

Division of Infection and Immunity
Glasgow Biomedical Research Centre
University of Glasgow
120 University Place
Glasgow G12 8TA
UK

David Molyneux

Director of the Lymphatic Filariasis
Support Centre
Liverpool School of Tropical
Medicine
Liverpool, UK

Samantha J. Moss

Neonatal Department
Royal Victoria Infirmary
Newcastle upon Tyne
NE1 4LP
UK

Hanna Nohynek

Department of Vaccines
Clinical Unit
National Public Health Institute
Mannerheimintie 166
FIN-00300
Helsinki, Finland

Eric Ottesen

Task Force for Child Survival
Emory University
Atlanta, GA,
USA

Umesh Parashar

Viral Gastroenteritis Section
CDC
1600 Clifton Road
Atlanta, GA 30333
USA

David A. Randolph

Department of Paediatrics and Division of
Immunology
Stanford University
CCSR Building
Room 2115
Stanford University School of Medicine
269 Campus Drive
Stanford, CA 94305-5164
USA

Frank Shann

Intensive Care Unit
Royal Children's Hospital
Melbourne Australia
and
University of Melbourne Australia

Matthew J. Thompson

Department of Primary Health Care
University of Oxford
Old Road Campus
Oxford OX3 7LF UK

Sam Walters

Senior Lecturer Pediatric Infectious
Diseases
Imperial College of Science and Medicine
London
and
Honorary Consultant Pediatrician
Department of Paediatrics
St Mary's Hospital
Paddington
London W2 1NY, UK

Adilia Warris

Pediatric Infectious Diseases Specialist
Radboud University Medical Center
Nijmegen
P.O. Box 9101
6500 HB Nijmegen, the Netherlands

Pablo Yagupsky

Clinical Microbiology Laboratories
Soroka University Medical Center
Ben-Gurion
University of the Negev
Beer-Sheva 84101
Israel

Frank Shann

Kathryn Maitland

Peter J. Hotez

Nigel Curtis

Roger Glass

David B. Lewis

Andrew Gennery

Toni Darville

Sailesh Kotecha

Tim J. Mitchell

B. Keith English

Hanna Nohynek

John S. Bradley

Robert S. Heyderman

Pablo Yagupsky

Nico Hartwig

Jonathan R. Carapetis

Hoosen Coovadia

Sam Walters

Paul Glasziou

Adam Finn

Andrew J. Pollard